Answers are grounded in this paper and cite their sources.
Randomized controlled trial reveals no benefit of dexamethasone for migraine relapse in children and adolescents, suggesting reevaluation of its use.
In this small clinical trial of children and adolescents with acute migraine attack treated in the ED, adjunctive dexamethasone did not reduce relapse rates nor improve functional outcomes compared with placebo. Although limited by low statistical power, these findings raise questions about the routine use of dexamethasone in migraine management of children and adolescents.
No takes yet. Share an insight, caveat, or question.
Tourigny‐Ruel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: